Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 6/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1342912 | 0.89 | MAP2K1 (0.40) | MAP2K1FTOSMN1; SMN2DHODHKDM4E | |
| SCHEMBL3974178 | 0.89 | MAP2K1 (0.47) | SRCCSF1RALDH1A1LMNAGAA | |
| SCHEMBL3973762 | 0.89 | NUDT1 (0.42) | CSF1RMAP2K1DHODHKDM4E | |
| SCHEMBL3978440 | 0.82 | CLCN2 (0.42) | CSF1RALDH1A1GAAMAPTMAP2K1 | |
| SCHEMBL13841993 | 0.82 | MAP2K1 (0.48) | CSF1RMAP2K1 | |
| SCHEMBL14499986 | 0.81 | IRAK4 (0.41) | CSF1RLMNAMAP2K1SMN1; SMN2 | |
| SCHEMBL15088100 | 0.81 | FTO (0.42) | FTOFABP3FABP4DHODHPPARG | |
| SCHEMBL1488337 | 0.81 | MAP2K1 (0.53) | MAP2K1 | |
| SCHEMBL4088292 | 0.81 | L3MBTL1 (0.42) | ALDH1A1GAAMAPTMAP2K1FTO | |
| SCHEMBL3974682 | 0.81 | MAP2K1 (0.53) | MAP2K1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673339-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1673339-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7511058-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7271178-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7230099-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230099-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230099-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007022529-A2 | METHOD OF TREATING INFLAMMATORY DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-7144907-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060189668-A1 | Method of treating hyperproliferative disorders using heterocyclic inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1673339-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060030610-A1 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005023759-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | SRC 199/4885CSF1R 1571/4885ALDH1A1 1431/4885 |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | SRC 146/4885CSF1R 1633/4885ALDH1A1 1609/4885 |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | SRC 164/4885CSF1R 1664/4885ALDH1A1 1721/4885 |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | SRC 146/4885CSF1R 1633/4885ALDH1A1 1609/4885 |
| US-20060030610-A1 | Method of treating inflammatory diseases | TNF, MPO, FABP2 | SRC 2361/4885CSF1R 1311/4885ALDH1A1 408/4885 |
| US-20060189668-A1 | Method of treating hyperproliferative disorders using heterocyclic inhibitors of MEK | NRAS, BRAF, RAF1 | SRC 199/4885CSF1R 1863/4885ALDH1A1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.